OCT angiography biomarkers in type 1 choroidal neovascularisation after one year of aflibercept treatment

To assess the activity of biomarkers, through OCT angiography (OCTA), of choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) treated with aflibercept. As secondary endpoints, visual acuity (VA) and the relationship between biomarkers and visual prognosis were also...

Full description

Saved in:
Bibliographic Details
Published in:Archivos de la Sociedad Española de Oftalmología (English ed.) 2022-11, Vol.97 (11), p.639-645
Main Authors: Campos Polo, R., Gómez Sánchez, I.
Format: Article
Language:English
Subjects:
Aflibercept
Age-related macular degeneration
anti-VEGF
Choroidal neovascularisation
Degeneración macular asociada a la edad
Neovascularización coroidea
OCT angiography
OCT-angiografía
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the activity of biomarkers, through OCT angiography (OCTA), of choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) treated with aflibercept. As secondary endpoints, visual acuity (VA) and the relationship between biomarkers and visual prognosis were also studied. Prospective study that examined 33 eyes of 40 naïve patients with type 1 CNV secondary to AMD, who had been treated with aflibercept, according to summary of product characteristics, for one year. The patients were evaluated at the time of diagnosis, and at 4, 8 and 12 months. The mean VA gain at 12 months was 15.2 ± 3.3 letters. The area of lesion decreased 1.2 ± 1.0 mm2 in the 4th month (P 
ISSN:2173-5794
2173-5794
DOI:10.1016/j.oftale.2021.02.005